Showing results (281-290 of 306) with videos related to

Sort By:
Pageof 31
Journal of Acquired Immune Deficiency Syndromes (1999)|March 17, 2022
Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 EpidemicsKatharina Kusejko, Nadine Tschumi, Sandra E Chaudron, et al.
ACS Medicinal Chemistry Letters|May 31, 2021
Discovery of a Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase with Oral Anti-Inflammatory ActivityMark S Tichenor, John J M Wiener, Navin L Rao, et al.
The Journal of Experimental Medicine|May 26, 2018
Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activityClaus Kadelka, Thomas Liechti, Hanna Ebner, et al.
Mbio|January 25, 2024
Cross-protective HCoV immunity reduces symptom development during SARS-CoV-2 infectionIrene A Abela, Magdalena Schwarzmüller, Agne Ulyte, et al.
Nature|August 19, 2011
Broad neutralization coverage of HIV by multiple highly potent antibodiesLaura M Walker, Michael Huber, Katie J Doores, et al.
Plos One|January 24, 2025
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune functionAnnette Audigé, Alain Amstutz, Macé M Schuurmans, et al.
Nature Medicine|November 8, 2016
Determinants of HIV-1 broadly neutralizing antibody inductionPeter Rusert, Roger D Kouyos, Claus Kadelka, et al.
Microbial Genomics|May 12, 2023
The Swiss Pathogen Surveillance Platform - towards a nation-wide One Health data exchange platform for bacterial, viral and fungal genomics and associated metadataAitana Neves, Daniel Walther, Trinidad Martin-Campos, et al.
The Journal of Infectious Diseases|January 16, 2024
Deciphering Factors Linked With Reduced Severe Acute Respiratory Syndrome Coronavirus 2 Susceptibility in the Swiss HIV Cohort StudyIrene A Abela, Anthony Hauser, Magdalena Schwarzmüller, et al.
Viruses|April 27, 2024
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE TrialsCharlotte Hedskog, Christoph D Spinner, Ulrike Protzer, et al.
Pageof 31